Reportlinker Adds Mylan Inc.: PharmaVitae Profile

NEW YORK, March 4 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Mylan Inc.: PharmaVitae Profile

http://www.reportlinker.com/p0180117/Mylan-Inc-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Mylan in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Mylan's performance against key rivals in the prescription pharmaceutical sector

*Assess how the acquisition of Merck KGaA's generics division will impact Mylan's forecast performance

*Consider Mylan's strategy to maintain its position as the world's third largest generics company

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

Mylan: PharmaVitae forecasts at a glance 8

Strategic insight 9

1) 2002-06: Modest growth amid increasing US competition 10

2) 2007-09: M&A sustains position as third largest generics player 10

3) 2010-14: Profit growth via synergies and geographic expansion 11

SWOT analysis 13

Strengths 13

Weaknesses 14

Opportunities 14

Threats 14

TABLE OF CONTENTS 16

Table of figures 18

Chapter 3 Quarterly news update 19

Product developments 19

Deals and alliances 20

Product deals 20

M&A activity 21

Company announcements 22

Chapter 4 Company introduction 24

Key findings 24

Background 25

Key corporate developments 25

M&A history 25

Early M&A boosts branded Prescription pharmaceuticals capacity 26

Matrix acquisition provides API capabilities 26

Acquisition of Merck Generics 27

Mylan/Merck combination becomes third largest global generics player 27

The acquisition expands Mylan's geographical presence 27

Acquisition of Merck KGaA's CEE generics business 28

Mylan- potential for further M&A? 28

Current corporate structure 29

Generics Segment 29

Specialty Segment 29

Matrix Segment 30

Chapter 5 Company sales 31

Key findings 31

Prescription pharmaceutical sales and growth rate analysis, 2002-14 32

Product analysis 34

Product analysis, 2002-08 34

Product analysis, 2008-14 38

Therapy area analysis 42

Geographic analysis 45

Launch portfolio analysis 48

Launch analysis, 2008-14 48

Molecule type analysis 50

Externalization analysis 53

Chapter 6 Company financials 56

Key findings 56

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 57

Operating costs and profit analysis 58

Operating costs and profit analysis, 2002-08 59

Operating cost ratio and profit margin analysis, 2002-08 60

Operating cost ratio and profit margin analysis, 2008-14 61

Operating costs and profit analysis, 2008-14 63

Chapter 7 Key products and competitors 64

Overview 64

Central nervous system 65

EpiPen 65

Overview 65

Sales forecast 66

EpiPen sourced through Dey LP acquisition 66

Revenues affected by seasonal factors 66

Competition from Sciele's TwinJect 66

Next generation device launched in October 2009 67

Respiratory 68

Perforomist 68

Overview 68

Sales forecast 69

Perforomist offers advantages over DuoNeb 69

Competition expected from Sepracor's Brovana 69

DuoNeb 70

Overview 70

Sales forecast 71

DuoNeb to face declining sales over 2008-14 71

Oncology 72

gen. Xeloda 72

Mylan is forecast to launch a generic version of Roche's Xeloda (capecitabine) in 2013. This launch date is based upon the patent expiry of the branded colon and breast cancer drug, however, should Mylan successfully challenge this patent protection, Mylan could launch gen. Xeloda at an earlier date. Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Xeloda and expects to qualify for 180 days of sole marketing exclusivity once final FDA approval is obtained. Roche filed a lawsuit on April 8 2009 alleging Mylan's infringement of US patent no. 5,472,949. 72

Overview 72

Sales forecast 73

gen. Copaxone 74

Overview 74

Sales forecast 75

gen. Copaxone is product of Mylan's alliance with NATCO Pharma 75

Manufacturing complexity will prove an obstacle 75

Sandoz/Momenta offering expected to be first generic to US market 76

gen. fentanyl 77

Overview 77

Sales forecast 78

Mylan owns the majority of the fentanyl patch market 78

Teva enters the Duragesic market in Q3 2008 78

Recall in 2008 expected to have a lasting impact on generic sales 78

gen. Depakote ER 80

Overview 80

Sales forecast 81

Depakote ER generic launched in 2009 81

Sales to decline post-2009 81

Chapter 8 Appendix 82

References 82

Abbreviations 82

Exchange rates 83

About Datamonitor 84

About Datamonitor Healthcare 84

Datamonitor consulting 84

Disclaimer 86

LIST OF TABLES

Table 1: Mylan - PharmaVitae forecasts at a glance 8

Table 2: Mylan key product developments, 2009 19

Table 3: Mylan product deals and alliances, 2009 20

Table 4: Mylan M&A activity, 2009 21

Table 5: Mylan company announcements, 2009 22

Table 6: Mylan product portfolio overview ($m), 2002-08 34

Table 7: Mylan product portfolio overview ($m), 2008-14 38

Table 8: Mylan prescription pharmaceutical sales by therapy area ($m), 2008-14 43

Table 9: Mylan prescription pharmaceutical sales by geographic region ($m), 2008-14 46

Table 10: Mylan launch portfolio overview ($m), 2008-14 48

Table 11: Mylan prescription pharmaceutical sales by molecule type ($m), 2008-14 51

Table 12: Mylan prescription pharmaceutical sales by source ($m), 2008-14 54

Table 13: Total Mylan sales by business unit ($m), 2002-08 57

Table 14: Mylan operating revenue/cost analysis ($m), 2002-08 59

Table 15: Mylan operating cost ratio analysis (% of total revenues), 2002-08 60

Table 16: Mylan operating cost ratio analysis (% of total revenues), 2008-14 61

Table 17: Mylan operating revenue/cost analysis ($m), 2008-14 63

Table 18: Key products overview 64

Table 19: EpiPen: overview 65

Table 20: EpiPen: sales forecast ($m), 2008-14 66

Table 21: Perforomist: overview 68

Table 22: Perforomist: sales forecast ($m), 2008-14 69

Table 23: DuoNeb: overview 70

Table 24: DuoNeb: sales forecast ($m), 2008-14 71

Table 25: gen. Xeloda: overview 72

Table 26: gen. Xeloda: sales forecast ($m), 2008-14 73

Table 27: gen. Copaxone: overview 74

Table 28: gen. Copaxone: sales forecast ($m), 2008-14 75

Table 29: gen. fentanyl: overview 77

Table 30: gen. fentanyl: sales forecast ($m), 2008-14 78

Table 31: gen. Depakote ER: overview 80

Table 32: gen. Depakote ER: sales forecast ($m), 2008-14 81

Table 33: Exchange rates, 2009 83

LIST OF FIGURES

Figure 1: The PharmaVitae Explorer 3

Figure 2: Mylan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Mylan's financial performance ($m), 2002-14 7

Figure 4: Mylan: impact of M&A over 2002-14 9

Figure 5: Generic company ranking by prescription pharmaceuticals revenue ($m), 2002-14 11

Figure 6: Mylan SWOT analysis 13

Figure 7: Mylan key M&A developments 26

Figure 8: Current corporate structure 29

Figure 9: Mylan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 32

Figure 10: Mylan key sales growth drivers and resistors ($m), 2002-08 36

Figure 11: Mylan key sales growth drivers and resistors ($m), 2008-14 40

Figure 12: Mylan prescription pharmaceutical sales by therapy area ($m), 2002-14 42

Figure 13: Mylan prescription pharmaceutical sales by geographic region ($m), 2002-14 45

Figure 14: Mylan prescription pharmaceutical sales by molecule type ($m), 2002-14 50

Figure 15: Mylan prescription pharmaceutical sales by source ($m), 2002-14 53

Figure 16: Mylan operating revenue/cost analysis ($m), 2002-14 58

To order this report:

Prescription Drug Industry: Mylan Inc.: PharmaVitae Profile

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo